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Abstract—One important application of nanotechnology is that of 
drug delivery, and in particular the targeted delivery of drugs 
using nanotubes. A proper understanding of the encapsulation 
behavior of drug molecules into nanotubes is vital for the 
development of nanoscale drug delivery vehicles. Furthermore, 
there are many other materials which may form single-walled 
nanotubes, such as carbon, boron carbide, boron nitride and 
silicon, and it is also important to understand their advantages 
and disadvantages. This paper presents a synopsis of the recent 
work in which boron nitride, boron carbide and silicon 
nanotubes are examined as drug delivery vehicles, and their 
encapsulation behavior is compared to previous work of the 
authors on carbon nanotubes.  
Keywords-nanotubes; drug delivery; cisplatin; suction; 
acceptance 
I.  INTRODUCTION 
The idealized ‘magic bullet’ concept [1], first proposed at 
the beginning of the 20th  century is now becoming a reality 
due to the advent of nanotechnology, and in particular the use 
of nanoparticles and nanotubes as delivery vehicles. In 
principle, an ideal drug carrier is injected into the body and 
transports itself to the correct target, such as a tumor, and 
delivers the required dose at this target. Due to their precise 
targeting nature and their protective environment, these 
nanoscale drug carriers enable a stronger drug to be used at a 
lower dose, resulting in fewer of the adverse side effects which 
exist for current methods, such as the highly toxic 
chemotherapeutic cancer treatments. Also, nanocapsules offer 
improvements to drug delivery methods for infections, 
metabolic diseases, autoimmune diseases, and pain treatment 
as well as for gene therapy [1].  
To date, nanoparticles have been used for drug delivery and 
cosmetics and it has only been recently that nanotubes have 
gained significant attention. Nanotubes offer a number of 
advantages which suggest that they may provide an improved 
result [2]. Namely, they have a larger inner volume which 
allows more drug molecules to be encapsulated, and they have 
distinct inner and outer surfaces for functionalization. In 
addition, the volume and surfaces of the nanotube are more 
readily accessible since the end caps can be easily removed. 
Both nanoparticles and nanotubes have been shown to be 
readily taken up by cells [3, 4], and nanotubes have been found  
 
Figure 1.  Outline of the proposed drug delivery process. (a) Nanotube 
surface is functionalized with a chemical receptor and the drug molecules are 
encapsulated, (b) open end is capped, (c) nanocapsule is ingested and locates 
to target site due to functionalized surface, (d) cell internalizes the capsule for 
example by receptor mediated endocytosis, (c) cap is removed or biodegrades 
inside cell, and (f) drug molecules are released [7].  
to enter cell nuclei [5] suggesting another advantage in that 
they may be useful in gene therapy. The general proposed drug 
delivery process using nanotubes, in this case in the form of 
nano test tubes [6], is illustrated in Fig. 1.  
Ultimately, we want to design a nanotube carrier such that 
prior to delivery it is energetically favorable for the drug 
molecule to be encapsulated, and once inside the desired cell it 
is energetically favorable to be ejected. Thus, the contents are 
deposited to the target site. Understanding the encapsulation 
and expulsion of drug molecules from nanocarriers is vital for 
the development of nanoscale drug delivery. As stated by 
Ferrari [8] “Novel mathematical models are needed, in order to 
secure the full import of nanotechnology into oncology.”  
Motivated by recent research into the suction of fullerenes 
into carbon nanotubes [9], we investigate the encapsulation 
behavior of a particular anticancer drug molecule entering a 
nanotube using applied mathematical modeling techniques and 
elementary mechanics. In particular, we determine the 
minimum radius of nanotube that will accept the anticancer 
drug cisplatin into its interior, and we determine the tube radius The authors acknowledge support from the Australian Research Council 
1-4244-1504-7/08/$25.00 © 2008 IEEE ICONN 2008109
that provides the maximum drug uptake. Cisplatin is a platinum 
based anticancer drug which is used to treat a wide range of 
tumors, despite its adverse side effects. It is expected that this 
form of targeted nanoscale drug delivery will significantly 
reduce these adverse side effects.  
Single-walled nanotubes may be formed from a range of 
materials, such as carbon, boron nitride, boron carbide and 
silicon [10], and the list of possible materials is constantly 
growing [11]. Since their discovery, carbon nanotubes have 
generated considerable research and development for 
nanomechanical devices due to their demonstrated remarkable 
and unique electrical, mechanical, and optical properties. 
Nanotubes formed from alternative materials may be more 
biocompatible and be better for use in nanomedical devices, 
and as such it is important to understand the various advantages 
and disadvantages of these alternative materials. For example, 
boron nitride nanotubes share many of the excellent properties 
of carbon nanotubes because they share the same structure 
[12]. However, compared to carbon nanotubes, boron nitride 
nanotubes offer improved performance, through their high 
chemical stability, and high resistance to oxidation at high 
temperatures [13]. Furthermore, boron nitride tubes have 
already shown improvement over carbon nanotubes in the area 
of gigahertz oscillators [14, 15], in which boron nitride based 
oscillators generate higher oscillatory frequencies. Due to their 
biocompatibility [16, 17] boron nitride nanotubes may be 
particularly suitable for nanomedical applications. Similarly, 
silicon, with proven biocompatibility [18], has been widely 
used in the development of biomedical devices, such as neural 
prostheses and biochips, and therefore may also be a good 
material for nanomedical devices.  
This paper provides a synopsis of recent work by the 
authors [19], in which the encapsulation behaviors of the 
anticancer drug cisplatin entering a boron nitride, boron carbide 
and silicon nanotube are compared to earlier work investigating 
the encapsulation of cisplatin into carbon nanotubes [20]. Our 
aim is to determine if there is an improved encapsulation 
behavior for the alternative nanotube materials. The technique 
presented here may be applied to any particular drug molecule, 
provided that the atom coordinates are known. However, the 
drug cisplatin is chosen in the interest of drawing a direct 
comparison to our earlier work [20]. We comment that this 
paper draws on a mathematical formulation proposed in an 
earlier paper by the authors [21].  
II. METHOD 
A. Interaction energy, acceptance and suction 
The intermolecular forces between two interacting 
molecules is typically evaluated using either the discrete atom-
atom approach or by the continuum approach whereby the 
atoms are assumed to be uniformly distributed over the surface 
of each molecule. These approaches have their disadvantages, 
the discrete atom-atom formulation can be time consuming 
especially for large molecules, and the continuum approach is 
mostly applicable to highly symmetric structures. This paper 
utilizes the hybrid discrete-continuous approach [21] in which 
one molecule is represented discretely and the other 
continuously, thereby enabling irregular shaped molecules, 
such as drugs, to be represented whilst maintaining the time 
saving advantage of the continuous approach. Using the hybrid 




i∑ ∫= ρυη            (1) 
where η is the mean surface density of atoms on the 
continuously modeled molecule, υ(ρi) is the potential function, 
and ρi is the distance between atom i on the discretely modeled 
molecule and a typical surface element dS on the continuously 
modeled molecule. The hybrid model has been shown to 
compare well to the typically used, discrete atom-atom and 
continuous, methods [21]. Note that the various components of 
the interaction force are determined by the negative gradient of 
the interaction energy (1). In particular, due to symmetry, of 
specific interest is the axial force, which is given by F = 
−dE/dZ and illustrated in Fig. 2. 
In this paper the potential function υ(ρi) is described by the 
Lennard-Jones potential which applies to non-bonded, non-
polar atomic interactions, and is given by 
( ) ,126 −− +−= ρρρυ BA                     (2) 
where A and B are the attractive and repulsive constants, 
respectively. In some cases, such as in this investigation, the 
force constants for the interaction between two atoms is 
unavailable, and the empirical combining rules [20, 22] may be 
used to determine approximate constants. Typically, a solvent 
medium is used to deliver drug molecules, and although this is 
not specifically addressed in this paper it may be incorporated 
by adjusting the Lennard-Jones constants by a factor of the 
dielectric constant of the solvent [20, 22]. 
To understand the encapsulation behavior of a particular 
drug molecule as it enters a nanotube the concepts of an 
acceptance condition and the suction energy [23] are used. 
With reference to Fig. 2, a particular molecule (located at 
negative Z and with no initial velocity) will be accepted into 
the nanotube interior (positive Z) by van der Waals forces 
alone provided that the work done or acceptance energy Wa 
from –∞ to Z0 (the positive root of the interaction force, as 
shown in Fig. 2) is positive. Fig. 3 illustrates the typical 
behavior of the acceptance energy against nanotube radius a, 
noting that the point where the curve crosses the x-axis, labeled 
a0, is the minimum radius of nanotube that will accept a 
particular molecule by van der Waals forces alone.  
Similarly, the suction energy W is the work done generated 
by van der Waals interactions acquired by a particular 
molecule as a consequence of being sucked into the nanotube 
interior. Fig. 4 illustrates a typical suction energy, which 
crosses the x-axis at amin and has a maximum at a nanotube 
radius amax. Note that when the nanotube radius is equal to amin 
it is energetically favorable for the molecule to be inside the 
nanotube. However, when the radius is in the range amin < a < 
a0, an additional energy is required for the molecule to be 
encapsulated. For further details the reader is referred to Hilder 





Figure 2.  Typical interaction force between a drug molecule and a nanotube. 
Note that negative Z is outside the nanotube and positive Z is inside. 
Figure 3.  Typical acceptance energy for a drug molecule entering a nanotube 
of radius a, with the minimum radius of acceptance a0 indicated. 
Figure 4.  Typical suction energy for a drug molecule entering a nanotube of 
radius a, with the energetically favorable radius amin, and the maximum uptake 
radius amax indicated. 
B. Nanotube materials 
A carbon nanotube can be thought of as a sheet of graphite 
rolled up into a seamless hollow cylinder. Similarly, boron 
nitride, boron carbide and silicon can all form graphite-like 
nanotubes [11, 12, 24-31]. However, silicon nanowires have 
been observed much more readily [32] due to the preference of 
sp3 bonding [33], despite this, silicon nanotubes have been 
reported experimentally [30, 31]. By use of the empirical 
combining rules [20, 22], the Lennard-Jones constants are 
determined and are summarized in Table I [19, 20]. For further 
details of the method used we refer the reader to [19-21]. 
TABLE I.  LENNARD-JONES CONSTANTS 
Atom A (eV×Å6) B (eV×Å12) 
Boron-boron 27.91 47304 
Nitrogen-nitrogen 36.48 52955 
Carbon-carbon 19.96 34792 
Silicon-silicon 436.91 2742630 
Chlorine-chlorine 612.76 3445961 
Hydrogen-hydrogen 10.51 5363 
Platinum-platinum 287.85 1044434 
III. RESULTS AND DISCUSSION 
Following Hilder and Hill [20], three orientations of 
cisplatin are examined. Table II outlines approximate values 
for the nanotube radii which provide acceptance a0, maximum 
suction amax, and the energetically favorable radius amin. More 
specifically, to accept all three orientations of cisplatin the 
nanotube must have a radius of at least 4.895 Å, 4.875 Å, 4.894 
Å and 5.226 Å for carbon (CNT), boron nitride (BNNT), boron 
carbide (BCNT) and silicon (SiNT) nanotubes, respectively 
[19]. The boron nitride nanotube has the smallest radius for 
acceptance, and thus the smallest radius to be efficiently filled 
with cisplatin. Accordingly, the boron nitride nanotube requires 
the least amount of material to deliver the drug, and as a result 
provides the least toxicity. Once the drug is ejected inside the 
cell the remaining nanocapsule may either slowly clear from 
the body or may remain, thus it is vital to reduce the amount of 
material required for efficient encapsulation. Alternatively, a 
silicon nanotube requires the largest radius for acceptance. 
Comparing the magnitude of the suction energy at the 
maximum suction location illustrates a notable difference 
between all four materials, and the order from the lowest to the 
highest magnitude is boron carbide, boron nitride, carbon and 
silicon. In particular, the magnitude for the silicon nanotube is 
significantly larger than the other three materials. For 
encapsulation this is a positive result, since a larger suction 
energy results in a more efficient encapsulation. However, 
upon expulsion there will be a higher energy barrier for the 
encapsulated molecule to overcome. Therefore, the smaller 
suction energies are preferable as they provide efficient 
encapsulation in addition to minimizing the barrier upon 
expulsion.  
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TABLE II.  RADIUS OF NANOTUBE AT ENERGETICALY FAVORABLE  
VALUE amin, ACCEPTANCE a0, AND MAXIMUM SUCTION amax 
Orientation and corresponding radii (Å) 
(i) (ii) (iii)  
amin a0 amax amin a0 amax amin a0 amax 
CNTa 4.76 4.80 5.34 4.76 4.90 5.34 4.74 4.79 5.27 
BNNTb 4.76 4.77 5.3 4.76 4.88 5.3 4.71 4.75 5.23 
BCNTb 4.78 4.79 5.34 4.78 4.89 5.34 4.74 4.78 5.27 
SiNTb 5.12 5.13 5.73 5.12 5.23 5.73 5.08 5.13 5.67 
a. Hilder and Hill [20], b. Hilder and Hill [19]  
IV. CONCLUSIONS 
In summary, the boron nitride nanotube provides the most 
ideal delivery capsule in terms of minimizing the amount of 
material required for encapsulation, thus providing the least 
toxicity. This technique, used to represent the encapsulation of 
cisplatin entering carbon, boron nitride, boron carbide and 
silicon nanotubes, can be extended to any number of drug 
molecules or alternative nanotube materials. It may be used to 
provide overall guidelines to assist in future experimental and 
molecular dynamics studies. It is hoped that in future work the 
expulsion of the drug molecule, once the nanocapsule is inside 
the cell, may be investigated. However, the expulsion occurs 
in an extremely complicated environment and presents 
challenges in terms of how best to model this environment. 
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